# Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation

> **NCT01800643** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hospital Israelita Albert Einstein** · enrollment: 100 (estimated)

## Conditions studied

- Acute Leukemia
- Chronic Leukemia
- Lymphoproliferative Disease
- Myeloproliferative Disease
- Immunodeficiency

## Interventions

- **OTHER:** Analyze the pharmacokinetics of busulfan for transplantation

## Key facts

- **NCT ID:** NCT01800643
- **Lead sponsor:** Hospital Israelita Albert Einstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-03
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01800643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01800643, "Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01800643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*